Is HRT safe for most women?
Yes, for healthy women under 60 who start within 10 years of menopause, the benefit-risk ratio is generally favorable. The KEEPS Continuation Study, which followed women for about 14 years after starting HRT in early menopause, found no long-term cognitive harm—and no cognitive benefit either—providing strong reassurance about neurocognitive safety [3]. A large UK case-control study of over 43,000 breast cancer cases found that the overall increased risk was small (odds ratio 1.12) and was driven almost entirely by synthetic progestins; estrogen alone and micronized progesterone showed no significant increase [4]. The American College of Cardiology-led review, citing four major medical societies, recommends HRT for bothersome symptoms in appropriate candidates [7].
What are the real risks I should know about?
The biggest concern—breast cancer—is real but nuanced. The UK case-control study found that synthetic progestins (like medroxyprogesterone acetate) increased risk (odds ratio 1.28), while micronized progesterone and estrogen alone did not [4]. This means the type of progestogen matters greatly. Psychiatric side effects are also possible: a real-world FDA database analysis of over 43,000 reports found that 6.6% involved psychiatric adverse events, with higher risk in women under 40 and with systemic (vs. local) administration [1]. However, a separate clinical trial of 152 women found that HRT actually improved mood and sleep compared to no HRT, with no difference in adverse reaction rates (6.58% vs. 9.21%) [2]. The apparent contradiction likely reflects that women who need HRT often have more severe symptoms at baseline, as a large UK Biobank study noted [9].
Who should avoid HRT?
Women with a history of hormone-sensitive cancers need careful evaluation. For endometrial cancer survivors, a small Japanese study of 33 women found no recurrences after a median of 2.6 years on HRT [6]. For cervical adenocarcinoma, a small UK study of 58 women found no survival detriment and even a trend toward better survival with HRT [8]. However, these are small studies, and individual counseling is essential. Women over 60 or those more than 10 years past menopause onset have a less favorable risk profile, especially for cardiovascular disease [10]. Compounded 'bioidentical' hormones, despite marketing claims, lack FDA approval and safety data; the American College of Obstetricians and Gynecologists advises against their routine use [5].
About These Sources
This answer is built on 10 peer-reviewed studies — published from 2021 to 2026, 4 from 2024 or later, 5 in Q1 journals, collectively cited 353 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 68 papers retrieved from a database of over 500 million.
Sources used in this answer
Psychiatric safety associated with hormone replacement therapy for menopausal symptoms: a real-world study of the FDA adverse event reporting system
In a real-world FDA database analysis of over 43,000 HRT-related reports, 6.6% involved psychiatric adverse events; risk was higher in women under 40 and with systemic (vs. local) administration, and estrogen alone increased mood and sleep issues while combination therapy increased depressed mood.
Effects of hormone replacement therapy on mood and sleep quality in menopausal women
In a randomized trial of 152 menopausal women, HRT significantly improved menopausal symptoms, mood, and sleep quality compared to conventional treatment alone, with no significant difference in adverse reaction rates (6.58% vs. 9.21%).
Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study
The KEEPS Continuation Study, following 275 women about 14 years after randomization, found no long-term cognitive harm or benefit from short-term HRT started in early menopause, providing reassurance about neurocognitive safety.
Menopausal Hormone Therapy Formulation and Breast Cancer Risk
In a large UK case-control study of over 43,000 breast cancer cases, the overall increased risk with HRT (OR 1.12) was driven by synthetic progestins (OR 1.28); estrogen alone and micronized progesterone showed no significant increase.
Compounded Bioidentical Menopausal Hormone Therapy
The American College of Obstetricians and Gynecologists states that compounded bioidentical hormones lack FDA approval and safety evidence, and should not be routinely prescribed over FDA-approved formulations.
Profiling of menopausal symptoms and therapeutic effects of hormone replacement therapy (HRT) in endometrial cancer survivors
In a retrospective study of 33 endometrial cancer survivors on HRT, 96% reported symptom improvement and no recurrences occurred during a median follow-up of 2.6 years.
Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?
A review by the American College of Cardiology and leading gynecologists recommends HRT for bothersome symptoms in appropriate candidates, emphasizing that timing, route, and formulation affect cardiovascular risk.
Safety of hormone replacement therapy in women with a history of cervical adenocarcinoma
In a retrospective study of 58 women with cervical adenocarcinoma, HRT use was not associated with worse survival; there was a non-significant trend toward better disease-specific survival (95% vs. 73% at 5 years).
Emotional and cognitive effects of menopause and hormone replacement therapy.
In a UK Biobank analysis of nearly 125,000 women, menopause was linked to more anxiety, depression, and sleep difficulties; HRT users had more mental health challenges, likely due to pre-existing symptoms rather than HRT itself.
Management of perimenopausal and menopausal symptoms
A clinical review states that estrogen-based therapies are the most effective treatment for menopausal symptoms and have a generally favorable benefit-risk ratio for women under 60 and within 10 years of menopause onset.